Discrete Particles In Supporting Matrix Patents (Class 424/469)
  • Patent number: 10300021
    Abstract: The present invention provides an intraorally rapidly disintegrating tablet that can be formed using an ordinary apparatus, that has hardness with no practical problem and that disintegrates rapidly with good feeling in the oral cavity. The present invention is intraorally rapidly disintegrating tablet produced by compression molding of a granule coated with a disintegrant, in which the granule contains a disintegrant also inside thereof and a drug except ambroxol hydrochloride inside and/or outside thereof.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: May 28, 2019
    Assignee: Teijin Pharma Limited
    Inventors: Tomoya Akutagawa, Masahiko Narasaki
  • Patent number: 10238102
    Abstract: A composite particle comprises i) an hydrophobic particle that adheres to the cuticle of one or more species of animal infesting arthropod; and ii) at least one organic chemical compound admixed therewith, wherein the said organic chemical is capable of controlling the population of at least one animal infesting arthropod species. Experiments proved the efficacy of the particle, for example in powder form, in relation to a variety of arthropods, for example red poultry mites.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: March 26, 2019
    Assignee: Exosect Limited
    Inventors: Clare Gillian Storm, Nicola Jane Huggett
  • Patent number: 10226462
    Abstract: The present invention relates to a method of treating or preventing hair loss or excessive hair shedding in a subject by administering to a subject an oral dose of minoxidil. In particular, the present invention relates to a method of treating telogen effluvium in a subject by administering to a subject an oral dose of minoxidil.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: March 12, 2019
    Assignee: Samson Clinical Pty Ltd
    Inventor: Rodney Sinclair
  • Patent number: 10179130
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 15, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
  • Patent number: 10172828
    Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: January 8, 2019
    Assignee: iCeutica Pty Ltd.
    Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch
  • Patent number: 10117449
    Abstract: The present invention relates to a process for the production of extruded formulations (=extrudates) comprising dispersion droplets, to such formulations as well as to the use of such formulations in food, feed, personal care applications.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: November 6, 2018
    Assignee: DSM IP ASSETS B.V.
    Inventors: Petrus Henricus Maria Elemans, Adrian Willem Meesen, Alexandra Teleki, Bruno Leuenberger
  • Patent number: 10080721
    Abstract: The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the dosage form exhibiting a breaking strength of at least 300 N and having an oblong shape comprising a longitudinal direction of extension, a transversal direction of extension orthogonal to the longitudinal direction of extension, a front side, an opposite back side and a circumferential rim between said front and back side; wherein the core of the pharmaceutical dosage form has a morphological orientation caused by hot-melt extrusion that is substantially orthogonal to the longitudinal direction of extension of the dosage form; and/or the release per area of the pharmacologically active ingredient (A) through the front side and the opposite back side is faster than the release through the circumferential rim.
    Type: Grant
    Filed: July 21, 2010
    Date of Patent: September 25, 2018
    Assignee: GRUENENTHAL GMBH
    Inventors: Lutz Barnscheid, Eric Galia
  • Patent number: 9943489
    Abstract: The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for extended release of active compounds useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and injuries to the nervous system. The active compound comprised within these compositions is preferably selected from N-propargyl-1-aminoindan, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: April 17, 2018
    Assignee: PHARMATWOB LTD.
    Inventors: Yoram Sela, Nurit Livnah, Itschak Lamensdorf, Tomer Madmon
  • Patent number: 9820948
    Abstract: The present invention concerns a new composition based on pellets of lipoic acid in a lipophilic medium, if necessary combined with other active ingredients.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: November 21, 2017
    Assignee: Olon S.p.A.
    Inventors: Paolo Magri', Antonio Nardi, Annibale Salvi, Flavio Villani
  • Patent number: 9789065
    Abstract: A process for producing solid oral dosage forms with controlled active ingredient release, comprising a mixture of a) at least one active ingredient, and b) a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone, wherein the mixture is obtained by joint processing of components a) and b) in an extruder at temperatures between 50° and 200° C.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: October 17, 2017
    Assignee: BASF SE
    Inventors: Karl Kolter, Angelika Maschke
  • Patent number: 9744136
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: August 29, 2017
    Assignee: Purdue Pharma L.P.
    Inventor: Haiyong Hugh Huang
  • Patent number: 9743688
    Abstract: Flavorants are emulsified in tobacco-derived lipids and encapsulated with biopolymers and polysaccharides. The emulsions include oil-in-water emulsions, oil-in-water-in-oil emulsions, water-in oil emulsions, or water-in-oil-in-water emulsions, and optionally include ethanol and/or propylene glycol in an oil phase.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: August 29, 2017
    Assignee: Philip Morris USA Inc.
    Inventors: Tapashi Sengupta, Munmaya K. Mishra, Douglas A. Fernandez, William R. Sweeney, Tony M. Howell
  • Patent number: 9682043
    Abstract: This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful for the delivery of the active agent, as well as compositions comprising the mixed phase co-crystals.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: June 20, 2017
    Assignee: MedCrystalForms, LLC
    Inventor: David Goldman
  • Patent number: 9572779
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: February 21, 2017
    Assignee: Purdue Pharma L.P.
    Inventor: Haiyong Hugh Huang
  • Patent number: 9545402
    Abstract: A pharmaceutical composition for oral administration comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one monolactate monohydrate, a filler in an amount of 15 to 70% by weight, a disintegrant in an amount of less than 15% by weight, a glidant and/or a lubricant in an amount of 0.1 to 10% by weight wherein the amounts by weight are based on the total weight of the composition.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: January 17, 2017
    Assignee: Novartis AG
    Inventors: Jeewan Thakur, Zhihui Qiu
  • Patent number: 9522118
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: December 20, 2016
    Assignee: Purdue Pharma L.P.
    Inventor: Haiyong Hugh Huang
  • Patent number: 9511029
    Abstract: The present invention provides an intraorally rapidly disintegrating tablet that can be formed using an ordinary apparatus, that has hardness with no practical problem and that disintegrates rapidly with good feeling in the oral cavity. The present invention is intraorally rapidly disintegrating tablet produced by compression molding of a granule coated with a disintegrant, in which the granule contains a disintegrant also inside thereof and a drug except ambroxol hydrochloride inside and/or outside thereof.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: December 6, 2016
    Assignee: Teijin Pharma Limited
    Inventors: Tomoya Akutagawa, Masahiko Narasaki
  • Patent number: 9393206
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: July 19, 2016
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventor: Haiyong Hugh Huang
  • Patent number: 9375482
    Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: June 28, 2016
    Assignee: University of Geneva
    Inventors: Michael Moller, Thomas Trimaille, Robert Gurny
  • Patent number: 9345715
    Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 24, 2016
    Assignee: SATIOGEN PHARMACEUTICALS, INC.
    Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
  • Patent number: 9320717
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: April 26, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
  • Patent number: 9278074
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 8, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
  • Patent number: 9271939
    Abstract: The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and/or water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: March 1, 2016
    Assignee: Inventia Healthcare Private Limited
    Inventors: Sunil Deviprasad Tiwari, Vijayendrakumar Virendrakumarji Redasani, Prasad Shrikantrao Joshi, Vaibhav Narayan Sawarkar, Ankur Janak Shah
  • Patent number: 9233078
    Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an amine-functionalized methacrylate copolymer.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 12, 2016
    Assignee: Bend Research, Inc.
    Inventors: Corey J. Bloom, Marshall David Crew, Warren Kenyon Miller
  • Patent number: 9198862
    Abstract: Disclosed herein is a dispersible tablet composition including a pharmacologically active ingredient and at least one excipient that reduces the sedimentation rate of the active ingredient and a process for preparing the same.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: December 1, 2015
    Assignee: Rubicon Research Private Limited
    Inventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi, Pradnya Bagde, Varsha Barve
  • Patent number: 9192679
    Abstract: The invention relates to a novel galenical system for taste masking, protecting an active substance, in particular in an acid medium, modulating releasing properties, masking mucous irritability and toxicity of certain active substances, for preparing aqueous forms which have a masked taste, are stable and pH independent. Said invention also relates, in particular to a galenical system which is embodied in the form of lipidic solid particles and strictly hydrophobic and devoid of water, surface active agents, emulsifiers, solvent traces and which is characterized in that it comprises at least one type of hydrophobic wax and at least one type of fatty non-neutralised acid.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: November 24, 2015
    Assignee: Capsugel France SAS
    Inventors: Karim Ioualalen, Rosanne Raynal
  • Patent number: 9192641
    Abstract: The current invention is a supplement made from a combination of herbs, vitamins, amino acids which in the preferred embodiment is a 100% vegetarian liquid capsules that are ingested allow for rapid absorption. The components of the supplement can be mint or menthol such as peppermint or spearmint, Methyl B12 or B12, Niacin, Guarana, Dimethylaminoethanol, Acetyl-L-carnitine or ALCAR, Ocimum tenuiflorum, one or more teas such as green tea, white tea or black tea, Ginkgo, Rhodiola rosea, phosphatidylserine, Tyrosine, L-Alpha Glycerylphosphorylcholine, Citicoline (INN), Huperzine A, and Vinpocetine.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: November 24, 2015
    Inventor: Shaahin Cheyene
  • Patent number: 9168226
    Abstract: The present invention provides an injectable particle comprising dasatinib acetate and a hyaluronic acid. The hyaluronic acid may be acetylated or sulfated. The particle is for the use of cancer therapy. The injectable particle may further comprises an acid, wherein the acid is dispersed evenly in the matrix of the injectable particle.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 27, 2015
    Inventor: David Wong
  • Patent number: 9125948
    Abstract: The present invention provides a method and composition for loading one or more drugs in a solution onto one or more ion exchange resin particles to form a drug-loaded resin particle. The drug-loaded resin particle is separated from the solution and dried before recombining the drug-loaded resin particle with the solution to load more drugs onto the drug-loaded resin particle from the solution.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: September 8, 2015
    Assignee: Coating Place, Inc.
    Inventors: Harlan Hall, J. Scott Madsen
  • Patent number: 9107835
    Abstract: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated aspirin active ingredient, and preferably a lightly compressed matrix comprising directly compressible carbohydrate(s) and at least one sweetener.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: August 18, 2015
    Assignee: McNeil-PPC, Inc.
    Inventors: Manoj N. Shah, James S. Beahm, Robert Shen
  • Patent number: 9107825
    Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: August 18, 2015
    Assignee: ZOMANEX, LLC
    Inventor: Curtis A. Spilburg
  • Patent number: 9078900
    Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active risperidone at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of risperidone to tissues or organs.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: July 14, 2015
    Assignee: BRAEBURN PHARMACEUTICALS BVBA SPRL
    Inventors: Petr Kuzma, Harry Quandt
  • Patent number: 9050258
    Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: June 9, 2015
    Assignee: AstraZeneca AB
    Inventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
  • Publication number: 20150110870
    Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Inventors: Benjamin Oshlack, Hua-Pin HUANG, John K. Masselink, Alfred Tonelli
  • Publication number: 20150110871
    Abstract: The present invention relates to a gastric retentive tablet composition comprising: (1) coated particles essentially consisting of a drug and an amino methacrylate copolymer, (2) a methacrylic acid copolymer and (3) an excipient, wherein items 1, 2, and 3 are blended together, and then compressed into a gastric retentive tablet. Thus, the coated particles (item 1), a methacrylic acid copolymer and the excipient are evenly distributed in the tablet. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a chelating agent, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof. The coated particles (item 1) do not contain methacrylic acid polymer.
    Type: Application
    Filed: January 3, 2015
    Publication date: April 23, 2015
    Inventor: David Wong
  • Patent number: 9000046
    Abstract: Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: April 7, 2015
    Assignee: Depomed, Inc.
    Inventors: Bret Berner, Cuiping Chen
  • Patent number: 8999386
    Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: April 7, 2015
    Assignee: TRIS Pharma, Inc.
    Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala
  • Patent number: 8968776
    Abstract: The invention provides new benzimidazole compositions, comprising: (a) a core containing said benzimidazole active ingredient; (b) an intermediate layer; and (c) an enteric layer; said core being substantially free of binder. The invention also provides a process for manufacturing the composition of the invention.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: March 3, 2015
    Assignee: UCB, Inc.
    Inventors: Pawan Seth, Benoît Schmitt
  • Patent number: 8962019
    Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: February 24, 2015
    Assignee: Angelini Pharma, Inc.
    Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
  • Patent number: 8962022
    Abstract: The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: February 24, 2015
    Assignee: Aptalis Pharmatech, Inc.
    Inventor: Gopi Venkatesh
  • Publication number: 20150037409
    Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 5, 2015
    Inventors: Benjamin Oshlack, Hua-Pin HUANG, John K. Masselink, Alfred Tonelli
  • Patent number: 8927013
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: January 6, 2015
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Patent number: 8927016
    Abstract: This invention provides a production method for a solid sustained-release preparation, characterized in that a sustained-release preparation (a sustained-release preparation suspension) is freeze-dried in a freeze-drying container whose inner face is partially or totally coated with an ice layer or water-repelling base material.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: January 6, 2015
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Hisayoshi Shimizu, Muneo Nonomura, Tomomichi Futo, Kei Mukai
  • Patent number: 8927014
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a superabsorbent material. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material creates a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: January 6, 2015
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Patent number: 8920833
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the coreswells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: December 30, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8920834
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a first layer and a second layer. The core comprises a superabsorbent material (for example, polycarbophil), and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to create a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: December 30, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8911780
    Abstract: An L-menthol-containing multiparticulate formulation includes a plurality of individual enteric coated cores containing L-menthol from an at least 80% pure L-menthol source. The enteric coated cores are effective to release at least about 35% of the L-menthol within about two hours, and at least about 80% of the L-menthol within about eight hours after being placed in an environment having a pH of 5 to 8. The L-menthol multiparticulate formulation can be used to treat gastrointestinal disorders.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: December 16, 2014
    Assignee: Zx Pharma, LLC
    Inventors: Syed Shah, Fred Hassan, Daniel Hassan, Sarah Hassan
  • Patent number: 8895064
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: November 25, 2014
    Assignee: Cosmo Technologies Limited
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 8877238
    Abstract: Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatinib, preferably imatinib monomethanesulfonate, wherein (i) the tablet cores and the granules have been produced by pressing of the starting materials and, prior to pressing of the starting materials, at least one of them has been dry-granulated, preferably compacted; (ii) the tablet cores and granule cores contain the active ingredient in a proportion of 25% by weight to 80% by weight, based on the total weight of the tablet cores or granule cores, together with (iii) at least one filler-binder, and optionally contain other additives; and (iv) the mean particle size distribution of at least 80% of the active ingredient is in the range from 0.01 mm to 1.0 mm.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: November 4, 2014
    Assignee: Siegfried International AG
    Inventors: Lambert Tillmann Röhrich, Beat W. Müller
  • Patent number: 8871269
    Abstract: The methods disclosed herein are of use for the production of controlled release compositions. In particular, the methods provide the contacting of an organic phase containing a bioactive agent and a polymer with an aqueous phase containing an organic ion to create controlled release compositions containing bioactive agents. The present invention also includes controlled release compositions including a polymer, an organic ion and a bioactive agent. The present invention also includes methods of using such controlled release compositions. The usefulness of the present invention is that the methods result in the production of controlled release compositions containing bioactive agent capable of administration in a concentrated low-dose form, having low burst and reduced production of degraded bioactive agent.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: October 28, 2014
    Assignee: Evonik Corporation
    Inventor: Gary P. Cook